For instance, BioNTech’s individualized mRNA vaccine BNT122 (RO7198457), developed in collaboration with Genentech, was tested in a Phase I trial in patients with solid tumors, including RCC, with measurable CD4+/CD8+ T-cell responses and signs of antitumor activity [14]. Here, CD4 is linked to renal cell carcinoma.